Peter van der Meer

List of Publications by Year
in descending order

249 papers	34,269 citations	13865 67 h-index	3732 179 g-index
253 all docs	253 docs citations	253 times ranked	33483 citing authors

#	Article	IF	Citations
1	Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF. Cardiovascular Research, 2022, 118, 1964-1977.	3.8	10
2	Rationale and Design of the Groningen Intervention Study for the Preservation of Cardiac Function with Sodium Thiosulfate after St-segment Elevation Myocardial Infarction (GIPS-IV) trial. American Heart Journal, 2022, 243, 167-176.	2.7	12
3	Pathophysiological pathways in patients with heart failure and atrial fibrillation. Cardiovascular Research, 2022, 118, 2478-2487.	3.8	5
4	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Circulation, 2022, 145, 87-89.	1.6	28
5	Patiromer for the management of hyperkalaemia in patients receiving reninâ€“angiotensinâ€“aldosterone system inhibitors for heart failure: design and rationale of the <scp>DIAMOND</scp> trial. European Journal of Heart Failure, 2022, 24, 230-238.	7.1	32
6	Additional burden of iron deficiency in heart failure patients beyond the cardioâ€renal anaemia syndrome: findings from the <scp>BIOSTATâ€CHF</scp> study. European Journal of Heart Failure, 2022, 24, 192-204.	7.1	20
7	Keratin 14 Degradation and Aging in Epidermolysis Bullosa Simplex due to KLHL24 Gain-of-Function Variants. Journal of Investigative Dermatology, 2022, 142, 2271-2274.e6.	0.7	4
8	Pathophysiology and risk factors of peripartum cardiomyopathy. Nature Reviews Cardiology, 2022, 19, 555-565.	13.7	21
9	Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the <scp>REPORTâ€HF</scp> registry. European Journal of Heart Failure, 2022, 24, 645-652.	7.1	18
10	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2022, 118, 3016-3051.	3.8	30
11	Natriuresisâ€guided therapy in acute heart failure: rationale and design of the <scp>Pragmatic Urinary Sodiumâ€based treatment algoritHm</scp> in <scp>Acute Heart Failure</scp> (<scp>PUSHâ€AHF</scp>) trial. European Journal of Heart Failure, 2022, 24, 385-392.	7.1	26
12	High selenium levels associate with reduced risk of mortality and newâ€onset heart failure: data from <scp>PREVEND</scp>. European Journal of Heart Failure, 2022, 24, 299-307.	7.1	19
13	Immune checkpoint inhibitorâ€“associated myocarditis. Netherlands Heart Journal, 2022, 30, 295-301.	0.8	8
14	A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With ReducedÂEjectionÂFraction. JACC: Heart Failure, 2022, 10, 73-84.	4.1	115
15	Micronutrient deficiencies in heart failure: Mitochondrial dysfunction as a common pathophysiological mechanism?. Journal of Internal Medicine, 2022, 291, 713-731.	6.0	23
16	Antisense Therapy Attenuates Phospholamban p.(Arg14del) Cardiomyopathy in Mice and Reverses Protein Aggregation. International Journal of Molecular Sciences, 2022, 23, 2427.	4.1	5
17	Functional investigation of two simultaneous or separately segregating DSP variants within a single family supports the theory of a doseâ€dependent disease severity. Experimental Dermatology, 2022, , .	2.9	3
18	Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology. Journal of Clinical Medicine, 2022, 11, 125.	2.4	45

#	Article	IF	Citations
19	Fluctuating iron levels in heart failure: when and where to look at?. European Journal of Heart Failure, 2022, 24, 818-820.	7.1	1
20	Clinical implications of low estimated protein intake in patients with heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2022, , .	7.3	7
21	A deleterious interaction between omecamtiv mecarbil and atrial fibrillation in patients with heart failure: an influence of digoxin?. European Heart Journal, 2022, 43, 2221-2223.	2.2	6
22	Selenium deficiency is associated with new-onset atrial fibrillation in PREVEND: a prospective general population cohort. European Journal of Preventive Cardiology, 2022, 29, .	1.8	0
23	Practical Guidance for Diagnosing and Treating Iron Deficiency in Patients with Heart Failure: Why, Who and How?. Journal of Clinical Medicine, 2022, 11, 2976.	2.4	5
24	Review: Precision Medicine Approaches for Genetic Cardiomyopathy: Targeting Phospholamban R14del. Current Heart Failure Reports, 2022, 19, 170-179.	3.3	6
25	A circular RNA derived from the insulin receptor locus protects against doxorubicin-induced cardiotoxicity. European Heart Journal, 2022, 43, 4496-4511.	2.2	41
26	High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality. European Journal of Heart Failure, 2021, 23, 919-932.	7.1	46
27	Impact of sex-specific target dose in chronic heart failure patients with reduced ejection fraction. European Journal of Preventive Cardiology, 2021, 28, 957-965.	1.8	13
28	Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. European Journal of Heart Failure, 2021, 23, 68-78.	7.1	79
29	Electrocardiographic features and their echocardiographic correlates in peripartum cardiomyopathy: results from the ESC EORP PPCM registry. ESC Heart Failure, 2021, 8, 879-889.	3.1	18
30	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure, 2021, 23, 527-540.	7.1	37
31	ATPase Inhibitory Factor-1 Disrupts Mitochondrial Ca2+ Handling and Promotes Pathological Cardiac Hypertrophy through CaMKIIΐ´. International Journal of Molecular Sciences, 2021, 22, 4427.	4.1	9
32	Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISEâ€MI): design and baseline characteristics. European Journal of Heart Failure, 2021, 23, 1040-1048.	7.1	70
33	Selenium, Selenoproteins, and Heart Failure: Current Knowledge and Future Perspective. Current Heart Failure Reports, 2021, 18, 122-131.	3.3	40
34	FC 021EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE IN PATIENTS WITH IRON DEFICIENCY FOLLOWING ACUTE HEART FAILURE, ACCORDING TO BASELINE EGFR: A SUBGROUP ANALYSIS OF THE AFFIRM-AHF TRIAL. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	1
35	Effects of sodiumâ€“glucose coâ€transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure. European Journal of Heart Failure, 2021, 23, 1049-1052.	7.1	2
36	Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction. ESC Heart Failure, 2021, 8, 2458-2466.	3.1	13

#	Article	IF	Citations
37	Improvement in left ventricular ejection fraction after pharmacological up-titration in new-onset heart failure with reduced ejection fraction. Netherlands Heart Journal, 2021, 29, 383-393.	0.8	5
38	Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population. Journal of the American Heart Association, 2021, 10, e018549.	3.7	51
39	Dynamic loading of human engineered heart tissue enhances contractile function and drives a desmosome-linked disease phenotype. Science Translational Medicine, 2021, 13, .	12.4	48
40	The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. Journal of Cardiac Failure, 2021, 27, 808-811.	1.7	7
41	Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients. European Journal of Heart Failure, 2021, 23, 1677-1686.	7.1	11
42	Prehospital risk stratification in patients with chest pain. Emergency Medicine Journal, 2021, 38, 814-819.	1.0	17
43	Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy. Nature Communications, 2021, 12, 5180.	12.8	24
44	Hypertensive disorders in women with peripartum cardiomyopathy: insights from the <scp>ESC</scp> EORP PPCM Registry. European Journal of Heart Failure, 2021, 23, 2058-2069.	7.1	20
45	Gain-of-function mutation in ubiquitin ligase KLHL24 causes desmin degradation and dilatation in hiPSC-derived engineered heart tissues. Journal of Clinical Investigation, 2021, 131, .	8.2	22
46	Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)â€“Related Cardiomyopathy: Development of PLN-R14delâ€“Related Cardiomyopathy. Circulation: Heart Failure, 2021, 14, e008532.	3.9	17
47	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. European Heart Journal, 2021, 42, 3011-3020.	2.2	71
48	Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management. European Journal of Preventive Cardiology, 2021, 28, 611-621.	1.8	33
49	Selenoprotein DIO2 Is a Regulator of Mitochondrial Function, Morphology and UPRmt in Human Cardiomyocytes. International Journal of Molecular Sciences, 2021, 22, 11906.	4.1	13
50	Iron deficiency in heart failureâ€”time to redefine. European Journal of Preventive Cardiology, 2021, 28, 1647-1649.	1.8	12
51	Efficacy of intravenous ferric carboxymaltose in patients with acute heart failure and iron deficiency with and without anaemia: a subgroup analysis of AFFIRM-AHF. European Heart Journal, 2021, 42, .	2.2	1
52	An Erythropoietin-Independent Mechanism of Erythrocytic Precursor Proliferation Underlies Hypoxia Tolerance in Sea Nomads. Frontiers in Physiology, 2021, 12, 760851.	2.8	0
53	Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci. Molecular Psychiatry, 2020, 25, 2392-2409.	7.9	83
54	The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. Clinical Research in Cardiology, 2020, 109, 331-338.	3.3	28

#	Article	IF	Citations
55	Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. European Journal of Heart Failure, 2020, 22, 1147-1155.	7.1	50
56	Myocardial dysfunction in longâ€term breast cancer survivors treated at ages 40â€“50â€‰years. European Journal of Heart Failure, 2020, 22, 338-346.	7.1	25
57	In peripartum cardiomyopathy plasminogen activator inhibitor-1 is a potential new biomarker with controversial roles. Cardiovascular Research, 2020, 116, 1875-1886.	3.8	20
58	Genetic risk and atrial fibrillation in patients with heart failure. European Journal of Heart Failure, 2020, 22, 519-527.	7.1	15
59	Potassium abnormalities in patients with heart failure from 11 Asian regions: insights from the ASIANâ€HF registry. European Journal of Heart Failure, 2020, 22, 751-754.	7.1	4
60	Selenium and outcome in heart failure. European Journal of Heart Failure, 2020, 22, 1415-1423.	7.1	84
61	The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach. European Journal of Heart Failure, 2020, 22, 2102-2111.	7.1	24
62	Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals. Nature Genetics, 2020, 52, 1314-1332.	21.4	91
63	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet, The, 2020, 396, 1895-1904.	13.7	425
64	P566Activated amyloid-beta pathways in patients with atrial fibrillation and heart failure, a pathway analysis in BIOSTAT. Europace, 2020, 22, .	1.7	0
65	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> (<scp>HFA</scp>) of the <scp>European Society of Cardiology</scp> (<scp>ESC</scp>). European Journal of Heart Failure, 2020, 22, 2272-2289.	7.1	92
66	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. European Heart Journal, 2020, 41, 3787-3797.	2.2	101
67	Genetic Determinants of Electrocardiographic P-Wave Duration and Relation to Atrial Fibrillation. Circulation Genomic and Precision Medicine, 2020, 13, 387-395.	3.6	16
68	A Clinical Tool to Predict Low Serum Selenium in Patients with Worsening Heart Failure. Nutrients, 2020, 12, 2541.	4.1	16
69	Human iPSC-Derived Cardiomyocytes of Peripartum Patients With Cardiomyopathy Reveal Aberrant Regulation of Lipid Metabolism. Circulation, 2020, 142, 2288-2291.	1.6	8
70	Cardiac foetal reprogramming: a tool to exploit novel treatment targets for the failing heart. Journal of Internal Medicine, 2020, 288, 491-506.	6.0	20
71	Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues. Current Oncology Reports, 2020, 22, 67.	4.0	20
72	The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy. Scientific Reports, 2020, 10, 9819.	3.3	38

#	Article	IF	Citations
73	Longâ€term survivors of early breast cancer treated with chemotherapy are characterized by a proâ€inflammatory biomarker profile compared to matched controls. European Journal of Heart Failure, 2020, 22, 1239-1246.	7.1	30
74	Distinct Pathological Pathways in Patients With HeartÂFailure and Diabetes. JACC: Heart Failure, 2020, 8, 234-242.	4.1	25
75	Clinical importance of urinary sodium excretion in acute heart failure. European Journal of Heart Failure, 2020, 22, 1438-1447.	7.1	55
76	Genetically Determined High Levels of Iron Parameters Are Protective for Coronary Artery Disease. Circulation Genomic and Precision Medicine, 2020, 13, e002544.	3.6	2
77	Fibroblast growth factor 23 mediates the association between iron deficiency and mortality in worsening heart failure. European Journal of Heart Failure, 2020, 22, 903-906.	7.1	3
78	Urinary sodium evaluation: the missing target for diuretic treatment optimization in acute heart failure patients? Reply. European Journal of Heart Failure, 2020, 22, 1933-1934.	7.1	0
79	Red-light-sensitive BODIPY photoprotecting groups for amines and their biological application in controlling heart rhythm. Chemical Communications, 2020, 56, 5480-5483.	4.1	53
80	Effect of a tailored exercise intervention during or after chemotherapy on cardiovascular morbidity in cancer patients.. Journal of Clinical Oncology, 2020, 38, 12018-12018.	1.6	0
81	Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?. Cardiac Failure Review, 2020, 6, e21.	3.0	2
82	Cardio-Oncology Services: rationale, organization, and implementation. European Heart Journal, 2019, 40, 1756-1763.	2.2	195
83	Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomy. Familial Cancer, 2019, 18, 19-27.	1.9	6
84	Residual confounding in observational studies: new data from the old DIG trial. European Heart Journal, 2019, 40, 3342-3344.	2.2	7
85	Cancer and heart disease: associations and relations. European Journal of Heart Failure, 2019, 21, 1515-1525.	7.1	120
86	Trajectories of Changes in Renal Function in Patients with Acute Heart Failure. Journal of Cardiac Failure, 2019, 25, 866-874.	1.7	16
87	Hyperkalemia and Treatment With RAASÂInhibitors During Acute HeartÂFailure Hospitalizations and TheirÂAssociation With Mortality. JACC: Heart Failure, 2019, 7, 970-979.	4.1	26
88	Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet, The, 2019, 394, 1254-1263.	13.7	159
89	Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use. European Heart Journal, 2019, 40, 3616-3625.	2.2	69
90	ACC/AHA Versus ESC Guidelines onÂHeartÂFailure. Journal of the American College of Cardiology, 2019, 73, 2756-2768.	2.8	195

#	Article	IF	Citations
91	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure, 2019, 21, 827-843.	7.1	223
92	Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study. PLoS Medicine, 2019, 16, e1002818.	8.4	16
93	Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure. JAMA Cardiology, 2019, 4, 696.	6.1	43
94	Mitochondrial Function, Skeletal Muscle Metabolism, and Iron Deficiency in Heart Failure. Circulation, 2019, 139, 2399-2402.	1.6	15
95	The clinical significance of interleukinâ€6 in heart failure: results from the BIOSTATâ€CHF study. European Journal of Heart Failure, 2019, 21, 965-973.	7.1	172
96	Cardiac Function After Radiation Therapy for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 104, 392-400.	0.8	22
97	Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis. European Heart Journal, 2019, 40, 1287-1293.	2.2	39
98	Hyperkalaemia: aetiology, epidemiology, and clinical significance. European Heart Journal Supplements, 2019, 21, A6-A11.	0.1	23
99	2371Electrocardiographic features and their echocardiographic correlates in peripartum cardiomyopathy based on the EURObservational registry on PPCM. European Heart Journal, 2019, 40, .	2.2	0
100	Rationale and design of the AFFIRMâ€AHF trial: a randomised, doubleâ€blind, placeboâ€controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in ironâ€deficient patients admitted for acute heart failure. European Journal of Heart Failure, 2019, 21, 1651-1658.	7.1	42
101	Active smoking and macrocytosis in the general population: Two populationâ€based cohort studies. American Journal of Hematology, 2019, 94, E45-E48.	4.1	5
102	Treating oxidative stress in heart failure: past, present and future. European Journal of Heart Failure, 2019, 21, 425-435.	7.1	407
103	Concise Review: The Current State of Human In Vitro Cardiac Disease Modeling: A Focus on Gene Editing and Tissue Engineering. Stem Cells Translational Medicine, 2019, 8, 66-74.	3.3	27
104	Modeling Human Cardiac Hypertrophy in Stem Cell-Derived Cardiomyocytes. Stem Cell Reports, 2018, 10, 794-807.	4.8	49
105	Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. European Journal of Heart Failure, 2018, 20, 910-919.	7.1	225
106	Value of digoxin in patients with heart failure: new pieces to the puzzle. European Journal of Heart Failure, 2018, 20, 1146-1147.	7.1	6
107	Longâ€term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure, 2018, 20, 951-962.	7.1	101
108	Prevalence, clinical correlates, and outcomes of anaemia in multiâ€ethnic Asian patients with heart failure with reduced ejection fraction. ESC Heart Failure, 2018, 5, 570-578.	3.1	21

#	Article	IF	Citations
109	Heart Failure Stimulates Tumor Growth by Circulating Factors. Circulation, 2018, 138, 678-691.	1.6	229
110	Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure). Circulation: Heart Failure, 2018, 11, e004431.	3.9	13
111	Nâ€terminal proâ€Bâ€type natriuretic peptide and prognosis in <scp>Caucasian</scp> vs. <scp>Asian</scp> patients with heart failure. ESC Heart Failure, 2018, 5, 279-287.	3.1	8
112	Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients. Circulation: Heart Failure, 2018, 11, e004519.	3.9	147
113	Predicting heart failure: one size does not fit all. European Journal of Heart Failure, 2018, 20, 674-676.	7.1	0
114	Potassium and the use of reninâ€“angiotensinâ€“aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTATâ€CHF. European Journal of Heart Failure, 2018, 20, 923-930.	7.1	57
115	Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. International Journal of Cardiology, 2018, 253, 84-90.	1.7	55
116	Daily home BNP monitoring in heart failure for prediction of impending clinical deterioration: results from the HOME HF study. European Journal of Heart Failure, 2018, 20, 474-480.	7.1	19
117	Active Smoking and Hematocrit and Fasting Circulating Erythropoietin Concentrations in the General Population. Mayo Clinic Proceedings, 2018, 93, 337-343.	3.0	16
118	Iron deficiency and red cell indices in patients with heart failure. European Journal of Heart Failure, 2018, 20, 114-122.	7.1	54
119	Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide. American Journal of Cardiology, 2018, 121, 107-112.	1.6	22
120	Anemia in Heart Failure. JACC: Heart Failure, 2018, 6, 201-208.	4.1	65
121	FP387IRON DEFICIENCY, ERYTHROPOIETIN, AND FIBROBLAST GROWTH FACTOR 23 IN THE GENERAL POPULATION. Nephrology Dialysis Transplantation, 2018, 33, i164-i164.	0.7	0
122	5223Absolute and functional iron deficiency in heart failure defined and described. European Heart Journal, 2018, 39, .	2.2	0
123	Novel endotypes in heart failure: effects on guideline-directed medical therapy. European Heart Journal, 2018, 39, 4269-4276.	2.2	44
124	Metabolic Maturation of Human Pluripotent Stem Cell-Derived Cardiomyocytes by Inhibition of HIF1Îİ and LDHA. Circulation Research, 2018, 123, 1066-1079.	4.5	159
125	Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. European Journal of Heart Failure, 2018, 20, 1664-1672.	7.1	92
126	Association of different iron deficiency cutoffs with adverse outcomes in chronic kidney disease. BMC Nephrology, 2018, 19, 225.	1.8	35

#	Article	IF	Citations
127	Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. International Journal of Cardiology, 2018, 271, 132-139.	1.7	140
128	Cardiomyopathy in patients with epidermolysis bullosa simplex with mutations in KLHL24. British Journal of Dermatology, 2018, 179, 1181-1183.	1.5	23
129	Sexâ€specific associations of obesity and Nâ€terminal proâ€Bâ€type natriuretic peptide levels in the general population. European Journal of Heart Failure, 2018, 20, 1205-1214.	7.1	60
130	Waistâ€toâ€hip ratio and mortality in heart failure. European Journal of Heart Failure, 2018, 20, 1269-1277.	7.1	85
131	Exome-chip meta-analysis identifies novel loci associated with cardiac conduction, including ADAMTS6. Genome Biology, 2018, 19, 87.	8.8	47
132	OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fraction. Cardiovascular Research, 2018, 114, 1871-1882.	3.8	38
133	Identifying Pathophysiological Mechanisms in Heart Failure WithÂReduced Versus Preserved EjectionÂFraction. Journal of the American College of Cardiology, 2018, 72, 1081-1090.	2.8	199
134	LC-MS analysis of key components of the glutathione cycle in tissues and body fluids from mice with myocardial infarction. Journal of Pharmaceutical and Biomedical Analysis, 2018, 160, 289-296.	2.8	15
135	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. European Heart Journal, 2018, 39, 3867-3875.	2.2	47
136	Correlation with invasive left ventricular filling pressures and prognostic relevance of the echocardiographic diastolic parameters used in the 2016 ESC heart failure guidelines and in the 2016 ASE/EACVI recommendations: a systematic review in patients with heart failure with preserved ejection fraction. European Journal of Heart Failure, 2018, 20, 1303-1311.	7.1	138
137	Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. Circulation: Heart Failure, 2017, 10, .	3.9	11
138	Cardioâ€Oncology: Progress in Diagnosis and Treatment of Cardiac Dysfunction. Clinical Pharmacology and Therapeutics, 2017, 101, 481-490.	4.7	24
139	Reninâ€“Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction. Circulation: Heart Failure, 2017, 10, .	3.9	89
140	Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (<scp>PPCM</scp>). European Journal of Heart Failure, 2017, 19, 1131-1141.	7.1	163
141	Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. Heart, 2017, 103, 407-413.	2.9	74
142	Neuromodulation for systolic heart failure: more than a placebo effect?. European Journal of Heart Failure, 2017, 19, 401-403.	7.1	0
143	Discovery of novel heart rate-associated loci using the Exome Chip. Human Molecular Genetics, 2017, 26, 2346-2363.	2.9	29
144	Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure. International Journal of Cardiology, 2017, 243, 360-366.	1.7	42

#	Article	IF	Citations
145	Biomarker Profiles of AcuteÂHeartÂFailureÂPatients With aÂMid-Range EjectionÂFraction. JACC: Heart Failure, 2017, 5, 507-517.	4.1	78
146	Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction. Clinical Research in Cardiology, 2017, 106, 802-812.	3.3	30
147	Associations between volume status and circulating microRNAs in acute heart failure. European Journal of Heart Failure, 2017, 19, 1077-1078.	7.1	5
148	Long-term outcome of cardiac function in a population-based cohort of breast cancer survivors: AÂcross-sectional study. European Journal of Cancer, 2017, 81, 56-65.	2.8	29
149	Comorbidities in Heart Failure. Handbook of Experimental Pharmacology, 2017, 243, 35-66.	1.8	45
150	Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction. Journal of the American Heart Association, 2017, 6, .	3.7	164
151	Low circulating microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related rehospitalizations. Clinical Research in Cardiology, 2017, 106, 598-609.	3.3	66
152	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2017, 5, 92-98.	4.1	129
153	Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. European Journal of Heart Failure, 2017, 19, 1651-1660.	7.1	89
154	New Blood Pressureâ€“Associated Loci Identified in Meta-Analyses of 475â€‰000 Individuals. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	48
155	What have we learned about heart failure with midâ€range ejection fraction one year after its introduction?. European Journal of Heart Failure, 2017, 19, 1569-1573.	7.1	67
156	Clinical and Hemodynamic Correlates and Prognostic Value of VE/VCO 2 Slope in Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Hypertension. Journal of Cardiac Failure, 2017, 23, 777-782.	1.7	34
157	Singleâ€Cell Functional Analysis of Stemâ€Cell Derived Cardiomyocytes on Micropatterned Flexible Substrates. Current Protocols in Stem Cell Biology, 2017, 43, 1F.20.1-1F.20.9.	3.0	3
158	Diastolic Dysfunction is Common in Survivors of Pediatric Differentiated Thyroid Carcinoma. Thyroid, 2017, 27, 1481-1489.	4.5	16
159	Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH. Science Translational Medicine, 2017, 9, .	12.4	36
160	Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. Circulation, 2017, 136, 1374-1383.	1.6	289
161	Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial. Cardiovascular Drugs and Therapy, 2017, 31, 281-293.	2.6	8
162	Serum ferritin and risk for newâ€onset heart failure and cardiovascular events in the community. European Journal of Heart Failure, 2017, 19, 348-356.	7.1	38

#	Article	IF	Citations
163	Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. Journal of Cardiac Failure, 2017, 23, 231-239.	1.7	30
164	Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and healthâ€related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. European Journal of Heart Failure, 2017, 19, 116-125.	7.1	50
165	The LifeLines Cohort Study: Prevalence and treatment of cardiovascular disease and risk factors. International Journal of Cardiology, 2017, 228, 495-500.	1.7	79
166	Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.6	39
167	Rodent heart failure models do not reflect the human circulating microRNA signature in heart failure. PLoS ONE, 2017, 12, e0177242.	2.5	25
168	Meta-GWAS and Meta-Analysis of Exome Array Studies Do Not Reveal Genetic Determinants of Serum Hepcidin. PLoS ONE, 2016, 11, e0166628.	2.5	2
169	Signature of circulating <scp>microRNAs</scp> in patients with acute heart failure. European Journal of Heart Failure, 2016, 18, 414-423.	7.1	162
170	Optimizing clinical use of biomarkers in highâ€risk acute heart failure patients. European Journal of Heart Failure, 2016, 18, 269-280.	7.1	69
171	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2016, 37, 2129-2200.	2.2	13,008
172	Iron deficiency, anemia, and mortality in renal transplant recipients. Transplant International, 2016, 29, 1176-1183.	1.6	38
173	Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. International Journal of Cardiology, 2016, 224, 231-239.	1.7	53
174	Acute heart failure in the young: Clinical characteristics and biomarker profiles. International Journal of Cardiology, 2016, 221, 1067-1072.	1.7	11
175	Plasma kidney injury moleculeâ€1 in heart failure: renal mechanisms and clinical outcome. European Journal of Heart Failure, 2016, 18, 641-649.	7.1	32
176	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2016, 18, 891-975.	7.1	5,272
177	<scp>MicroRNAs</scp> in heart failure: from biomarker to target for therapy. European Journal of Heart Failure, 2016, 18, 457-468.	7.1	235
178	Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nature Genetics, 2016, 48, 1151-1161.	21.4	261
179	High serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria: data from PREVEND. European Journal of Heart Failure, 2016, 18, 814-821.	7.1	13
180	Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure, 2016, 18, 1096-1105.	7.1	160

#	Article	IF	Citations
181	Response: A Portable Device as Sleep-Screening Tool in the Identification of Obstructive Sleep Apnea in Chronic Heart Failure: Which Value Should We Consider as Cutoff?. Journal of Cardiac Failure, 2016, 22, 168.	1.7	1
182	Cardiotoxicity of breast cancer treatment: no easy solution for an important long-term problem. European Heart Journal, 2016, 37, 1681-1683.	2.2	11
183	Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia. Expert Opinion on Pharmacotherapy, 2016, 17, 1527-1538.	1.8	3
184	Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. Circulation: Heart Failure, 2016, 9, .	3.9	35
185	Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure. Expert Opinion on Investigational Drugs, 2016, 25, 117-127.	4.1	37
186	MicroRNAs relate to early worsening of renal function in patients with acute heart failure. International Journal of Cardiology, 2016, 203, 564-569.	1.7	35
187	Maintenance of serum potassium with sodium zirconium cyclosilicate (<scp>ZS</scp>â€9) in heart failure patients: results from a phase 3 randomized, doubleâ€blind, placeboâ€controlled trial. European Journal of Heart Failure, 2015, 17, 1050-1056.	7.1	143
188	Sleepâ€disordered breathing and chronic heart failure: changing position may be important. European Journal of Heart Failure, 2015, 17, 1219-1222.	7.1	4
189	Erythropoietin in the General Population: Reference Ranges and Clinical, Biochemical and Genetic Correlates. PLoS ONE, 2015, 10, e0125215.	2.5	38
190	Integrated Analysis of Contractile Kinetics, Force Generation, and Electrical Activity in Single Human Stem Cell-Derived Cardiomyocytes. Stem Cell Reports, 2015, 5, 1226-1238.	4.8	54
191	Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. European Heart Journal, 2015, 36, 2565-2573.	2.2	274
192	Diuretic response in acute heart failureâ€”an analysis from ASCEND-HF. American Heart Journal, 2015, 170, 313-321.e4.	2.7	110
193	Validity and Predictive Value of a Portable Two-Channel Sleep-Screening Tool in the Identification of Sleep Apnea inÂPatients With Heart Failure. Journal of Cardiac Failure, 2015, 21, 848-855.	1.7	17
194	Hemoglobin levels and new-onset heart failure in the community. American Heart Journal, 2015, 169, 94-101.e2.	2.7	18
195	Vitamin B12and folate deficiency in chronic heart failure. Heart, 2015, 101, 302-310.	2.9	26
196	Sleep-disordered Breathing in Heart Failure â€“ Current State of the Art. Cardiac Failure Review, 2015, 1, 16.	3.0	4
197	Peripartum cardiomyopathy: Euro Observational Research Program. Netherlands Heart Journal, 2014, 22, 396-400.	0.8	6
198	Prognostic value of Nâ€terminal pro Câ€type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction. European Journal of Heart Failure, 2014, 16, 958-966.	7.1	42

#	Article	IF	Citations
199	Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. European Heart Journal, 2014, 35, 2165-2173.	2.2	159
200	Co-morbidities in heart failure. Heart Failure Reviews, 2014, 19, 163-172.	3.9	48
201	Anemia is associated with an increased central venous pressure and mortality in a broad spectrum of cardiovascular patients. Clinical Research in Cardiology, 2014, 103, 467-476.	3.3	2
202	A Novel Approach to Drug Development in Heart Failure: Towards Personalized Medicine. Canadian Journal of Cardiology, 2014, 30, 288-295.	1.7	21
203	Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis. Nature Communications, 2014, 5, 4926.	12.8	192
204	Fibrosis Marker Syndecan-1 and Outcome in Patients With Heart Failure With Reduced and Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 457-462.	3.9	60
205	Iron deficiency and health-related quality of life in chronic heart failure: Results from a multicenter European study. International Journal of Cardiology, 2014, 174, 268-275.	1.7	147
206	The additive burden of iron deficiency in the cardiorenalâ€“anaemia axis: scope of a problem and its consequences. European Journal of Heart Failure, 2014, 16, 655-662.	7.1	59
207	Safety and clinical outcome of erythropoiesis-stimulating agents in patients with ST-elevation myocardial infarction: A meta-analysis of individual patient data. American Heart Journal, 2014, 168, 354-362.e2.	2.7	5
208	Concise Review: Engineering Myocardial Tissue: The Convergence of Stem Cells Biology and Tissue Engineering Technology. Stem Cells, 2013, 31, 2587-2598.	3.2	40
209	Long Term Effects of Epoetin Alfa in Patients with ST- Elevation Myocardial Infarction. Cardiovascular Drugs and Therapy, 2013, 27, 433-439.	2.6	12
210	Functional Differences in Engineered Myocardium from Embryonic Stem Cell-Derived versus Neonatal Cardiomyocytes. Stem Cell Reports, 2013, 1, 387-396.	4.8	43
211	Iron deficiency in chronic heart failure: An international pooled analysis. American Heart Journal, 2013, 165, 575-582.e3.	2.7	532
212	Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clinical Research in Cardiology, 2013, 102, 103-110.	3.3	171
213	Incremental Prognostic Power of Novel Biomarkers (Growth-Differentiation Factor-15,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 18 Advanced Chronic Heart Failure. American Journal of Cardiology, 2013, 112, 831-837.	1.6	86
214	The Predictive Value of Short-Term Changes in Hemoglobin Concentration in Patients Presenting With Acute Decompensated Heart Failure. Journal of the American College of Cardiology, 2013, 61, 1973-1981.	2.8	159
215	Neurohormonal and clinical sex differences in heart failure. European Heart Journal, 2013, 34, 2538-2547.	2.2	83
216	Erythropoietin and heart failure: the end of a promise?. European Journal of Heart Failure, 2013, 15, 479-481.	7.1	13

#	Article	IF	Citations
217	Inflammation and anaemia in a broad spectrum of patients with heart failure. Heart, 2012, 98, 1237-1241.	2.9	22
218	Heart failure highlights in 2011. European Journal of Heart Failure, 2012, 14, 1090-1096.	7.1	3
219	Cardiac regeneration in left ventricular dysfunction: are we asking the right questions?. European Journal of Heart Failure, 2012, 14, 1-4.	7.1	4
220	Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Annals of Medicine, 2011, 43, 60-68.	3.8	506
221	Erythropoiesis-Stimulating Agents and Heart Failure. Cardiovascular Therapeutics, 2011, 29, e52-e59.	2.5	5
222	The unfulfilled promise of erythropoietin in patients with MI. Nature Reviews Cardiology, 2011, 8, 425-426.	13.7	6
223	Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clinical Research in Cardiology, 2010, 99, 323-328.	3.3	393
224	Endogenous Erythropoietin and Outcome in Heart Failure. Circulation, 2010, 121, 245-251.	1.6	56
225	Stem cells in heart failure. European Journal of Heart Failure, 2010, 12, 642-644.	7.1	5
226	Response to Letter Regarding Article, â€œEndogenous Erythropoietin and Outcome in Heart Failureâ€. Circulation, 2010, 122, .	1.6	0
227	Erythropoietin, iron, or both in heart failure: FAIRâ€HF in perspective. European Journal of Heart Failure, 2010, 12, 104-105.	7.1	5
228	Red blood cell distribution width and 1â€year mortality in acute heart failure. European Journal of Heart Failure, 2010, 12, 129-136.	7.1	224
229	Asialoerythropoietin to Protect the Failing Heart. Journal of the American College of Cardiology, 2010, 56, 1959-1960.	2.8	6
230	Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart, 2009, 95, 1309-1314.	2.9	115
231	Anaemia and renal dysfunction in chronic heart failure. Heart, 2009, 95, 1808-1812.	2.9	24
232	Generation of Functional Ventricular Heart Muscle from Mouse Ventricular Progenitor Cells. Science, 2009, 326, 426-429.	12.6	202
233	Anemia and Mortality in Heart Failure Patients. Journal of the American College of Cardiology, 2008, 52, 818-827.	2.8	601
234	Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. European Heart Journal, 2008, 29, 1510-1515.	2.2	72

#	Article	IF	Citations
235	Lowâ€dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. European Journal of Heart Failure, 2008, 10, 22-29.	7.1	72
236	Erythropoietin in cardiovascular diseases: exploring new avenues. Clinical Science, 2008, 114, 289-291.	4.3	6
237	Anemia and erythropoietin in heart failure. Heart Failure Monitor, 2008, 6, 28-33.	0.7	6
238	Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. European Heart Journal, 2007, 28, 2018-2027.	2.2	210
239	Erythropoietin: Repair of the Failing Heart**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology. Journal of the American College of Cardiology, 2006, 48, 185-186.	2.8	14
240	Protective Effects of Erythropoietin in Cardiac Ischemia. Journal of the American College of Cardiology, 2006, 48, 2161-2167.	2.8	167
241	A Single Bolus of a Long-acting Erythropoietin Analogue Darbepoetin Alfa in Patients with Acute Myocardial Infarction: A Randomized Feasibility and Safety Study. Cardiovascular Drugs and Therapy, 2006, 20, 135-141.	2.6	176
242	Erythropoietin: From Hematopoiesis to Cardioprotection. Cardiovascular Drugs and Therapy, 2005, 19, 7-8.	2.6	8
243	Levels of Hematopoiesis Inhibitor N -Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart Failure. Circulation, 2005, 112, 1743-1747.	1.6	120
244	Hemoglobin levels and 30-day mortality in patients after myocardial infarction. International Journal of Cardiology, 2005, 100, 289-292.	1.7	70
245	Erythropoietin Induces Neovascularization and Improves Cardiac Function in Rats With Heart Failure After Myocardial Infarction. Journal of the American College of Cardiology, 2005, 46, 125-133.	2.8	232
246	Erythropoietin in cardiovascular diseases. European Heart Journal, 2004, 25, 285-291.	2.2	136
247	Timing of Erythropoietin Treatment for Cardioprotection in Ischemia/Reperfusion. Journal of Cardiovascular Pharmacology, 2004, 44, 473-479.	1.9	152
248	Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. European Journal of Heart Failure, 2004, 6, 853-859.	7.1	92
249	Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. Journal of the American College of Cardiology, 2004, 44, 63-67.	2.8	178